Medscape This observational cohort study sought to determine the effect of initial oral glucose-lowering class on subsequent need for additional anti-hyperglycemia therapy. Participants included 15,516 patients who were not previously treated for diabetes, in ...
American Pharmacists Association, pharmacist.com ... as dulaglutide include the low risk of hypoglycemia, especially when administered with metformin or a thiazolidinedione ; the weight-loss effects of these agents; and potential adherence benefits associated with drugs that only require once-weekly ...
Daytona Beach News-Journal I exercise, stay slim and think I am reasonably careful about my diet. Subtract the dark-chocolate habit and minus the Cheetos cravings, I make fairly good choices. So I was shocked to learn that my fasting blood sugars were bordering on high and my ... and more »
Everyday Health Sulfonylurea stimulates the release of insulin from the pancreas. While the medication does work quickly, it may cause severe low blood sugar, weight gain, nausea, and skin rashes. TZD, or Thiazolidinedione , helps improve the body's sensitivity to ... and more »
FDA.gov The U.S. Food and Drug Administration today approved Trulicity (dulaglutide), a once-weekly subcutaneous injection to improve glycemic control (blood sugar lev...
HealthDay The researchers found that around 40 percent of people taking a sulfonylurea, a thiazolidinedione , or a dipeptidyl peptidase 4 inhibitor (DPP-4 inhibitor) ad...
Diabetes In Control While 24.5% patients on metformin required an add-on oral medication , 37.1% of patients on sulfonylurea, 39.6% of patients on thiazolidinedione , and 36.2% patients on DPP-4 inhibitor required an add-on oral medication . Moreover, 5.1% of patients on ...
PR Newswire (press release) Actos has been a prescribed diabetes medication since 1999 and is type of thiazolidinedione (TZD) that has been connected to a variety of side effects such as bladder cancer, cardiovascular problems, liver issues and fractures. Often individuals and ... and more »
The Pharmaceutical Journal Only 24.5% of patients on metformin needed a second glucose-lowering medication , compared with 37.1% given a sulfonylurea, 39.6% treated with a thiazolidinedione and 36.2% with a DPP-4 inhibitor. For the latter three drugs , metformin was the most ...
